摘要
目的探讨丹参川芎嗪注射液联合阿加曲班对急性脑梗死患者D-二聚体及血清炎性细胞因子水平的影响。方法选取120例急性脑梗死患者,按照治疗方案分为3组。A组采用丹参川芎嗪治疗,B组采用阿加曲班治疗,C组采用丹参川芎嗪+阿加曲班治疗。比较3组患者的临床疗效及治疗前后D-二聚体、超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平的变化。结果C组患者总有效率及脑卒中专门化生存质量量表(SS-QOL)评分显著高于A组及B组(P<0.05)。治疗后,3组的D-二聚体、hs-CRP、IL-6、TNF-α水平较治疗前显著下降(P<0.05),且C组与A组及B组相比有显著差异(P<0.05)。结论采用丹参川芎嗪注射液联合阿加曲班治疗急性脑梗死安全可靠,可显著改善患者的神经功能缺失症状,降低炎性细胞因子水平,改善血液高凝状态。
Objective To explore the influence of Danshen Ligustrazine Injection combined with argatroban on levels of D-dimer and serum inflammatory cytokines in patients with acute cerebral infarction. Methods Totally 120 patients with acute cerebral infarction were divided into three groups according to treatment regimen. Group A was treated with Danshen Ligustrazine Injection, group B was treated with argatroban, and group C was treated with Danshen Ligustrazine Injection plus argatroban. The clinical effect and the changes of D-dimer, high-sensitivity Creactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α) were analyzed before and after treatment. Results The total effective rate and SS-QOL score of group C were significantly higher than those of group A and group B ( P <0.05). After treatment, the levels of D-dimer, hs-CRP, IL-6 and TNF-α in the three groups were significantly lower than those before treatment ( P <0.05), and there were significant differences between group C and group A, group B ( P <0.05). Conclusion Application of Danshen Ligustrazine Injection combined with argatroban is safe and reliable in the treatment of patients with acute cerebral infarction, which can significantly improve the symptoms of neurological deficit, reduce the levels of inflammatory cytokines and improve the hypercoagulability state of blood.
作者
眭晨燕
胡玲玲
王引明
SUI Chenyan;HU Lingling;WANG Yinming(Department of Neurology,Wuxi Integrated Hospital of Traditional Chinese Medicineand Western Medicine,Wuxi,Jiangsu,214000)
出处
《实用临床医药杂志》
CAS
2019年第11期14-16,19,共4页
Journal of Clinical Medicine in Practice
